2LVERU® or 2LVERU® JUNIOR

Phase 3

LLabo'Life

2LVERU® or 2LVERU® JUNIOR is one of 5 therapeutic programs targeting Common Wart. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Common WartRecruiting

Common WartPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Common Wart

#DrugCompanyPhaseTrials

Vistide

Gilead

Approved

—2

2LVERU® or 2LVERU® JUNIOR

LLabo'Life

Phase 3

1 3

Trexall

Jazz Pharmaceuticals

Preclinical

—4

Candida Antigen

UUniversity of Arkansas

Preclinical

1 5

CRYOTHERAPY

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

ApprovedRecruiting

Common Wart

NCT03977753

Clinical

Trials by Indication[1]

Common Wart1 trial

Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.

Recruiting·LLabo'Life·Approved·NCT03977753·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 2LVERU® or 2LVERU® JUNIOR. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 2LVERU® or 2LVERU® JUNIOR. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Labo'Life company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: LLabo'Life

2LVERU® or 2LVERU® JUNIOR

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Common Wart1 trial

References

Drug Info

Quick Facts

Related News